Core Laboratories Sees Q3 GAAP EPS $0.12-$0.20 vs $0.16 Est; Sees Sales $128.500M-$135.500M vs $131.330M Est

Benzinga Newsdesk www.benzinga.com Neutral 74.9%

Neg 0% Neu 74.9% Pos 0%

Core Laboratories (NYSE:CLB) is looking for Q3 GAAP EPS of $0.12-$0.20 vs $0.16 analyst estimate. sees sales of $128.500 million-$135.500 million vs $131.330 million analyst estimate.